IL DONG PHARMACEUTICAL CO., LTD. Logo

IL DONG PHARMACEUTICAL CO., LTD.

Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.

249420 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 서초구 바우뫼로27길 2, 서초구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IL DONG PHARMACEUTICAL CO., LTD. is a healthcare company specializing in the research, development, manufacturing, and commercialization of pharmaceutical products. The company's business spans finished drugs, active pharmaceutical ingredients (APIs), and contract manufacturing (CMO) services, utilizing its GMP-certified facilities. Its therapeutic focus includes metabolic disorders, respiratory diseases, oncology, cardiovascular conditions, and gastrointestinal diseases. Ildong Pharmaceutical is committed to innovation, advancing a robust pipeline of novel drug candidates such as oral GLP-1 agonists for diabetes/obesity and first-in-class treatments for fibrotic diseases, partly through its spin-off iLeadBMS. The company is actively expanding its global market presence through strategic partnerships, licensing, and exports.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for IL DONG PHARMACEUTICAL CO., LTD. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 129.5 KB
2025-09-11 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 42.4 KB
2025-09-09 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.5 MB
2025-07-30 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 16.9 KB
2025-07-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-07-30 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.2 KB
2025-07-30 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 18.4 KB

Automate Your Workflow. Get a real-time feed of all IL DONG PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for IL DONG PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Tego Science, Inc. Logo
Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.
South Korea 191420
Teva Pharmaceutical Industries Ltd. Logo
A leader in affordable generic drugs and innovative specialty treatments for complex diseases.
Israel TEVA
THERAGEN ETEX CO.,LTD. Logo
A biotech firm offering gene analysis and developing personalized cancer drugs.
South Korea 066700
TheraVet SA Logo Belgium ALVET
Thor Medical ASA Logo
Sustainably produces alpha-emitters from thorium for cancer therapies, without nuclear reactors.
Norway NANOV
Tikun Olam Cannbit Pharmaceuticals Ltd. Logo
A vertically integrated pharma company developing research-backed, EU-GMP medical cannabis products.
Israel TKUN
TiumBio Co., Ltd. Logo
Clinical-stage biopharma developing therapies for rare diseases, gynecology, and hemophilia.
South Korea 321550
TMS Co., Ltd Logo
Develops small molecule drugs from natural compounds for the global pharmaceutical market.
Japan 4891
Together Pharma Ltd. Logo
Researches and produces medical cannabis products for domestic and European patients.
Israel TGTR
A pharmaceutical specialist in drugs for renal, skin, and allergic diseases.
Japan 4551

Talk to a Data Expert

Have a question? We'll get back to you promptly.